Literature
Phagemid Display
- Maywald F, Boldicke T, Gross G, Frank R, Blocker H, Meyerhans A, Schwellnus K, Ebbers J, Bruns W, Reinhardt G, et al.(1988): Human pancreatic secretory trypsin inhibitor (PSTI) produced in active form and secreted from Escherichia coli.
Gene. 1988 Sep 7;68(2):357-69. Pubmed
- Boldicke T, Kindt S, Maywald F, Fitzlaff G, Bocher M, Frank R, Collins J (1988): Production of specific monoclonal antibodies against the active sites of human pancreatic secretory trypsin inhibitor variants by in vitro immunization with synthetic peptides.
Eur J Biochem. 1988 Aug 1;175(2):259-64.
Erratum in:
Eur J Biochem 1989 Feb 15;179(3):725. Pubmed
- Collins J, Szardenings M, Maywald F, Blocker H, Frank R, Hecht HJ, Vasel B, Schomburg D, Fink E, Fritz H (1990): Human leukocyte elastase inhibitors: designed variants of human pancreatic secretory trypsin inhibitor (hPSTI).
Biol Chem Hoppe Seyler. 1990 May;371 Suppl:29-36. Pubmed
- Szardenings M, Collins J (1990): A phasmid optimised for protein design projects: pMAMPF.
Gene. 1990 Sep 28;94(1):1-7. Pubmed
- Paulsen J, Kroner KH, Schuette H, Szardenings M, Hustedt H (1989): Membrane and adsorption processes in the purification of the human pancreatic secretory trypsin inhibitor (hPSTI)
Ber. Bunsenges. Phys. Chem. 93, 1015-1019(1989)
- Paulsen J. et al., DECHEMA Biotech. Conf., DECHEMA, Frankfurt, pp1031 (1989)
- Hecht HJ, Szardenings M, Collins J, Schomburg D (1991): Three-dimensional structure of the complexes between bovine chymotrypsinogen A and two recombinant variants of human pancreatic secretory trypsin inhibitor (Kazal-type).
J Mol Biol. 1991 Aug 5;220(3):711-22. Pubmed
- Collins, J. et al., in Wooley et al. (ed.) D.F.I. Print, Aarhus, pp34 (1990)
- Klaus W, Schomburg D (1993): Solution structure of a variant of human pancreatic secretory trypsin inhibitor determined by nuclear magnetic resonance spectroscopy.
J Mol Biol. 1993 Feb 5;229(3):695-706. Pubmed
- Hecht HJ, Szardenings M, Collins J, Schomburg D (1992): Three-dimensional structure of a recombinant variant of human pancreatic secretory trypsin inhibitor (Kazal type)
J Mol Biol. 1992 Jun 20;225(4):1095-103. Pubmed
- Szardenings M, Vasel B, Hecht HJ, Collins J, Schomburg D. (1995): Highly effective protease inhibitors from variants of human pancreatic secretory trypsin inhibitor (hPSTI): an assessment of 3-D structure-based protein design.
Protein Eng. 1995 Jan;8(1):45-52. Pubmed
- Roettgen P, Collins J (1995): A human pancreatic secretory trypsin inhibitor presenting a hypervariable highly constrained epitope via monovalent phagemid display.
Gene. 1995 Oct 27;164(2):243-50. Pubmed
- Zell R, Fritz HJ (1987): DNA mismatch-repair in Escherichia coli counteracting the hydrolytic deamination of 5-methyl-cytosine residues.
EMBO J. 1987 Jun;6(6):1809-15. Pubmed Free
- Tesar M, Beckmann C, Rottgen P, Haase B, Faude U, Timmis KN (1995): Monoclonal antibody against pIII of filamentous phage: an immunological tool to study pIII fusion protein expression in phage display systems.
Immunotechnology. 1995 May;1(1):53-64. Pubmed
- Beckmann C, Haase B, Timmis KN, Tesar M (1995): Multifunctional g3p-peptide tag for current phage display systems.
J Immunol Methods. 1998 Mar 15;212(2):131-8. Pubmed
- Marks JD, Hoogenboom HR, Griffiths AD, Winter G (1992): Minireview: Molecular evolution of proteins on filamentous phage. Mimicking the strategy of the immune system.
J Biol Chem. 1992 Aug 15;267(23):16007-10. Pubmed Free
- Dimasi N, Martin F, Volpari C, Brunetti M, Biasiol G, Altamura S, Cortese R, De Francesco R, Steinkuhler C, Sollazzo M (1997): Characterization of engineered hepatitis C virus NS3 protease inhibitors affinity selected from human pancreatic secretory trypsin inhibitor and minibody repertoires.
J Virol. 1997 Oct;71(10):7461-9. Pubmed Free
- Mersmann M, Schmidt A, Tesar M, Schoneberg A, Welschof M, Kipriyanov S, Terness P, Little M, Pfizenmaier K, Moosmayer D (1998): Monitoring of scFv selected by phage display using detection of scFv-pIII fusion proteins in a microtiter scale assay.
J Immunol Methods. 1998 Nov 1;220(1-2):51-8. Pubmed
- Hengerer A, Kosslinger C, Decker J, Hauck S, Queitsch I, Wolf H, Dubel S (1999): Determination of phage antibody affinities to antigen by a microbalance sensor system.
Biotechniques. 1999 May;26(5):956-60, 962, 964. Pubmed
- Kirsch M, Zaman M, Meier D, Dubel S, Hust M (2005): Parameters affecting the display of antibodies on phage.
J Immunol Methods. 2005 Jun;301(1-2):173-85. Pubmed
- Ballard VL, Holm JM, Edelberg JM (2006):
A quantitative PCR-based approach for rapid phage display analysis: a foundation for high throughput vascular proteomic profiling
Physiol Genomics. 2006 May 16; [Epub ahead of print] Pubmed
References with the pSKAN System
- Hengerer A, Decker J, Prohaska E, Hauck S, Kosslinger C, Wolf H (1999): Quartz crystal microbalance (QCM) as a device for the screening of phage libraries.
Biosens Bioelectron. 1999 Feb;14(2):139-44. Pubmed
- Verhaert RM, Van Duin J, Quax WJ (1999): Processing and functional display of the 86 kDa heterodimeric penicillin G acylase on the surface of phage fd.
Biochem J. 1999 Sep 1;342 ( Pt 2):415-22. Pubmed
- Noda K, Yamasaki R, Hironaka Y, Kitagawa A (2001): Selection of peptides that bind to the core oligosaccharide of R-form LPS from a phage-displayed heptapeptide library.
FEMS Microbiol Lett. 2001 Dec 18;205(2):349-54. Pubmed
- Cai D, Xaymardan M, Holm JM, Zheng J, Kizer JR, Edelberg JM (2003): Age-associated impairment in TNF-alpha cardioprotection from myocardial infarction.
Am J Physiol Heart Circ Physiol. 2003 Aug;285(2):H463-9. Epub 2003 May 1. Pubmed Free
- Edelberg JM, Wong A, Holm JM, Xaymardan M, Duignan I, Chin A, Kizer JR, Cai D (2004): Phage display identification of age-associated TNFalpha-mediated cardiac oxidative induction.
Physiol Genomics. 2004 Aug 11;18(3):255-60. Pubmed Free
- Cai D, Holm JM, Duignan IJ, Zheng J, Xaymardan M, Chin A, Ballard VL, Bella JN, Edelberg JM (2006): BDNF-mediated enhancement of inflammation and injury in the aging heart.
Physiol Genomics. 2006 Feb 14;24(3):191-7. Epub 2005 Dec 13. Pubmed Free
|